{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:54:04Z","timestamp":1788501244812,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-023-00864-0","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T03:31:37Z","timestamp":1685417497000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Should I stay or should I go (to transplant)? Managing insufficient responses to induction in multiple myeloma"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9670-2864","authenticated-orcid":false,"given":"Joseph R.","family":"Mikhael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"864_CR1","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"RA Kyle","year":"2008","unstructured":"Kyle RA, Rajkumar SV. ASH 50th anniversary review: multiple myeloma. Blood. 2008;111:2962\u201372.","journal-title":"Blood"},{"key":"864_CR2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3324\/haematol.2011.051441","volume":"97","author":"L Rosinol","year":"2012","unstructured":"Rosinol L, Garcia-Sanz R, Lahuerta JJ, Hernandez-Garcia M, Granell M, de la Rubia J, et al. Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. Haematologica. 2012;97:616\u201321.","journal-title":"Haematologica"},{"key":"864_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/sj.bmt.1703717","volume":"30","author":"S Singhal","year":"2002","unstructured":"Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant. 2002;30:673\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"864_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/sj.bmt.1704545","volume":"34","author":"S Kumar","year":"2004","unstructured":"Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant. 2004;34:161\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"864_CR5","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1182\/blood-2009-07-235531","volume":"115","author":"MA Gertz","year":"2010","unstructured":"Gertz MA, Kumar S, Lacy MQ, Dispenzieri A, Dingli D, Hayman SR, et al. Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood. 2010;115:2348\u201353.","journal-title":"Blood"},{"key":"864_CR6","doi-asserted-by":"publisher","first-page":"4529","DOI":"10.1200\/JCO.2013.49.0086","volume":"31","author":"P Kapoor","year":"2013","unstructured":"Kapoor P, Kumar SK, Dispenzieri A, Lacy MQ, Buadi F, Dingli D, et al. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol. 2013;31:4529\u201335.","journal-title":"J Clin Oncol"},{"key":"864_CR7","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00277-013-1911-1","volume":"93","author":"SE Lee","year":"2014","unstructured":"Lee SE, Yoon JH, Shin SH, Cho BS, Eom KS, Kim YJ, et al. Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma. Ann Hematol. 2014;93:627\u201334.","journal-title":"Ann Hematol"},{"key":"864_CR8","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1182\/blood-2010-08-300863","volume":"117","author":"P Moreau","year":"2011","unstructured":"Moreau P, Attal M, Pegourie B, Planche L, Hulin C, Facon T, et al. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood. 2011;117:3041\u20134.","journal-title":"Blood"},{"key":"864_CR9","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1182\/blood.V118.21.4135.4135","volume":"118","author":"N Shah","year":"2011","unstructured":"Shah N, Bashir Q, Parmar S, Dinh YT, Qureshi S, Rondon G, et al. Increased bone marrow plasma cell infiltration pre-transplant is associated with worse outcomes in patients undergoing high dose chemotherapy and autologous stem cell transplantation for multiple myeloma. Blood. 2011;118:4135.","journal-title":"Blood"},{"key":"864_CR10","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1080\/10428194.2016.1201572","volume":"58","author":"R Chakraborty","year":"2017","unstructured":"Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A, et al. Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. Leuk lymphoma. 2017;58:308\u201315.","journal-title":"Leuk lymphoma"},{"key":"864_CR11","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.1200\/JCO.2007.11.7879","volume":"25","author":"D Dingli","year":"2007","unstructured":"Dingli D, Pacheco JM, Nowakowski GS, Kumar SK, Dispenzieri A, Hayman SR, et al. Relationship between depth of response and outcome in multiple myeloma. J Clin Oncol. 2007;25:4933\u20137.","journal-title":"J Clin Oncol"},{"key":"864_CR12","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1200\/JCO.2008.17.9721","volume":"26","author":"JJ Lahuerta","year":"2008","unstructured":"Lahuerta JJ, Mateos MV, Martinez-Lopez J, Rosinol L, Sureda A, de la Rubia J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 2008;26:5775\u201382.","journal-title":"J Clin Oncol"},{"key":"864_CR13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.bbmt.2008.12.512","volume":"15","author":"JS Kim","year":"2009","unstructured":"Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, et al. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Biol Blood Marrow Transplant. 2009;15:463\u201370.","journal-title":"Biol Blood Marrow Transplant"},{"key":"864_CR14","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1182\/blood.V118.21.4119.4119","volume":"118","author":"S Farhan","year":"2011","unstructured":"Farhan S, Lin H, Baladandayuthapani V, Shah N, Bashir Q, Hosing CM, et al. Response before autologous hematopoietic stem cell transplantation is an important predictor of outcome in multiple myeloma. Blood. 2011;118:4119.","journal-title":"Blood"},{"key":"864_CR15","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1182\/blood.2021012319","volume":"138","author":"A Jim\u00e9nez-Ubieto","year":"2021","unstructured":"Jim\u00e9nez-Ubieto A, Paiva B, Puig N, Cedena M, Mart\u00ednez-L\u00f3pez J, Oriol A, et al. Validation of the International Myeloma Working Group standard response criteria in the PETHEMA\/GEM2012MENOS65 study: are these times of change? Blood. 2021;138:1901\u20135.","journal-title":"Blood"},{"key":"864_CR16","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1182\/blood-2018-99-116014","volume":"132","author":"GL Shah","year":"2018","unstructured":"Shah GL, Seier K, Devlin SM, Chung DJ, Scordo M, Hultcrantz M, et al. Depth of response and outcomes in patients with multiple myeloma undergoing autologous stem cell transplantation. Blood. 2018;132:4619.","journal-title":"Blood"},{"key":"864_CR17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.bbmt.2014.10.023","volume":"21","author":"R Vij","year":"2015","unstructured":"Vij R, Kumar S, Zhang MJ, Zhong X, Huang J, Dispenzieri A, et al. Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2015;21:335\u201341.","journal-title":"Biol Blood Marrow Transplant"},{"key":"864_CR18","doi-asserted-by":"publisher","first-page":"e616","DOI":"10.1016\/S2352-3026(19)30167-X","volume":"6","author":"GH Jackson","year":"2019","unstructured":"Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, et al. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol. 2019;6:e616\u2013e29.","journal-title":"Lancet Haematol"},{"key":"864_CR19","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1182\/blood-2014-07-590166","volume":"125","author":"AC Rawstron","year":"2015","unstructured":"Rawstron AC, Gregory WM, de Tute RM, Davies FE, Bell SE, Drayson MT, et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood. 2015;125:1932\u20135.","journal-title":"Blood"},{"key":"864_CR20","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4:5988\u201399.","journal-title":"Blood Adv"},{"key":"864_CR21","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41375-021-01293-3","volume":"35","author":"F Maura","year":"2021","unstructured":"Maura F, Weinhold N, Diamond B, Kazandjian D, Rasche L, Morgan G, et al. The mutagenic impact of melphalan in multiple myeloma. Leukemia. 2021;35:2145\u201350.","journal-title":"Leukemia"},{"key":"864_CR22","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1182\/blood.2022017094","volume":"141","author":"MK Samur","year":"2023","unstructured":"Samur MK, Roncador M, Samur AA, Fulciniti M, Bazarbachi AH, Szalat RE, et al. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma. Blood. 2023;141:1724\u201336. https:\/\/doi.org\/10.1182\/blood.2022017094.","journal-title":"Blood"},{"key":"864_CR23","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.bbmt.2018.02.017","volume":"24","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Stevenson PA, Libby EN, Becker PS, Coffey DG, Green DJ, et al. Circulating plasma cells at the time of collection of autologous PBSC for transplant in multiple myeloma patients is a negative prognostic factor even in the age of post-transplant maintenance therapy. Biol Blood Marrow Transplant. 2018;24:1386\u201391.","journal-title":"Biol Blood Marrow Transplant"},{"key":"864_CR24","doi-asserted-by":"publisher","first-page":"S421","DOI":"10.1016\/S2152-2650(22)01621-4","volume":"22","author":"O Pasvolsky","year":"2022","unstructured":"Pasvolsky O, Milton D, Rauf M, Ghanem S, Masood A, Mohamedi A, et al. MM-403 impact of clonal plasma cells in autografts on the outcome of high-risk multiple myeloma patients undergoing autologous hematopoietic stem cell transplant. Clin Lymphoma Myeloma Leuk. 2022;22:S421\u2013S2.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"864_CR25","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N. Engl J Med. 2017;376:1311\u201320.","journal-title":"N. Engl J Med"},{"key":"864_CR26","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N. Engl J Med. 2022;387:132\u201347.","journal-title":"N. Engl J Med"},{"key":"864_CR27","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1200\/JCO.18.00685","volume":"37","author":"EA Stadtmauer","year":"2019","unstructured":"Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol. 2019;37:589\u201397.","journal-title":"J Clin Oncol"},{"key":"864_CR28","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1016\/j.clml.2019.09.352","volume":"19","author":"K Chamoun","year":"2019","unstructured":"Chamoun K, De Lima M, Fu P, Caimi PF, Cao S, Gerson S, et al. Impact of regional income and insurance status on survival of multiple myeloma patients: autologous stem cell transplant as an equalizer. Clin Lymphoma Myeloma Leuk. 2019;19:e211\u2013e2.","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00864-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00864-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00864-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T03:32:25Z","timestamp":1685417545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00864-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["864"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00864-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"assertion":[{"value":"2 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.B.: Consulting: BMS, Caribou Biosciences, Genentech, Janssen, Sanofi, SparkCures; research support, Pack Health. L.W.: Consulting: BMS, Janssen, Abbvie. J.R.M.: Consulting: Amgen, BMS, Janssen, Karyopharm, Pfizer, Sanofi, Takeda.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}